Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

PEPGVery BullishCorporate Developmentsnews

High materiality9/10

PepGen Reports Highest Splicing Correction In Dystrophy Patients, Stock Doubles

Sep 25, 2025, 10:09 AM EDT1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

The significant rise in stock price (122.18%) reflects positive investor sentiment after favorable trial results, akin to other biotech stocks experiencing similar boosts from effective trial data.

AI summary

What happened, with direct paths to the underlying reporting

PepGen shares surged 122.18% to $5.91 amid high trading volume. FREEDOM-DM1 trial shows 53.7% splicing correction at 15 mg/kg dose. All patients at 15 mg/kg showed improved treatment response. Upcoming results from FREEDOM2-DM1 MAD expected in Q1 2026. Company raised $100 million through a share offering at $3.20.

PepGen shares surged 122.18% to $5.91 amid high trading volume.
FREEDOM-DM1 trial shows 53.7% splicing correction at 15 mg/kg dose.
All patients at 15 mg/kg showed improved treatment response.
Upcoming results from FREEDOM2-DM1 MAD expected in Q1 2026.
Company raised $100 million through a share offering at $3.20.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.